Athira Pharma Balance Sheet Health
Financial Health criteria checks 6/6
Athira Pharma has a total shareholder equity of $106.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $133.5M and $26.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$122.09m |
| Equity | US$106.74m |
| Total liabilities | US$26.72m |
| Total assets | US$133.46m |
Recent financial health updates
Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?
Feb 16
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?
Nov 02Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?
May 29Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?
Jan 04We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely
Aug 09Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth
May 08Recent updates
Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?
Feb 16Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?
Nov 02Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?
May 29Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?
Jan 04Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis
Oct 17Athira Pharma GAAP EPS of -$0.65
Aug 15We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely
Aug 09Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug
Jun 22Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth
May 08We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate
Jan 11Athira Pharma: What, Exactly, Did The CEO Do?
Jun 29Athira Pharma falls after the decision to place CEO on temporary leave
Jun 17Athira surges after Jefferies estimated 50% gain on FDA approval for Biogen’s Alzheimer’s therapy
Jun 07We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth
May 24We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely
Feb 08
Athira: Early Stage Alzheimer's Therapeutics With An Interesting Approach
Jan 11Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like
Dec 18Athira Pharma nabs research grant of $15M from NIH
Dec 08Athira Pharma reports Q3 results
Nov 12Financial Position Analysis
Short Term Liabilities: ATHA's short term assets ($128.6M) exceed its short term liabilities ($25.6M).
Long Term Liabilities: ATHA's short term assets ($128.6M) exceed its long term liabilities ($1.1M).
Debt to Equity History and Analysis
Debt Level: ATHA is debt free.
Reducing Debt: ATHA has no debt compared to 5 years ago when its debt to equity ratio was 95.4%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ATHA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ATHA has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 45.9% each year.